Humulin N

Humulin N is a recombinant human insulin (rDNA) supplied as an injectable solution for subcutaneous or intramuscular administration. It is a prescription‑only antidiabetic medication marketed in the European Union. The product contains insulin human (rDNA) as its active ingredient and is classified in the insulin therapeutic class. Humulin N is intended for use in adults with diabetes mellitus to provide basal insulin coverage, it is stored in a refrigerator until needed.

Humulin N is prescribed as a basal insulin to help manage blood glucose levels in patients with diabetes mellitus.

- Type 1 diabetes mellitus (adults and children) - Type 2 diabetes mellitus requiring basal insulin - Gestational diabetes when oral agents are insufficient - Adjunct therapy with rapid‑acting insulin for basal‑bolus regimens - Use in patients transitioning from other intermediate‑acting insulins - Supplemental basal insulin for patients with inadequate glycemic control on oral hypoglycemics alone - Part of a basal‑bolus insulin regimen in hospital settings for peri‑operative glucose management

Adverse reactions to Humulin N can vary in frequency and severity, ranging from mild injection‑site symptoms to rare systemic events.

Common: - Hypoglycemia, presenting as sweating, tremor, or confusion - Pain, redness or bruising at the injection site - Lipodystrophy (localized lipoatrophy or lipohypertrophy) at repeated injection sites - Weight gain associated with improved glycemic control - Mild allergic skin reactions such as rash or urticaria - Peripheral edema, especially with high doses - Transient visual disturbances such as blurred vision

Serious: - Severe hypoglycemia requiring assistance - Anaphylactic reaction with respiratory distress or shock - Significant hypokalemia leading to cardiac arrhythmias - Formation of insulin antibodies causing unpredictable glucose response - Acute pancreatitis with abdominal pain and elevated enzymes

When prescribing Humulin N, clinicians should evaluate patient‑specific factors and monitor for conditions that may alter insulin requirements or increase risk of adverse events.

- Assess renal and hepatic function because impairment may reduce insulin clearance. - Review history of hypoglycemia unawareness and adjust dose accordingly. - Consider pregnancy and lactation status; insulin requirements often change. - Evaluate for cardiovascular disease; rapid glucose shifts can affect cardiac stability. - Monitor weight and signs of fluid retention during therapy. - Screen for allergic reactions to insulin or excipients. - Educate patients on proper injection technique and rotation of sites.

Humulin N may interact with other medications that affect glucose metabolism, potassium balance, or insulin sensitivity, requiring dose adjustments or monitoring.

Avoid: - Concomitant use of other rapid‑acting insulins without proper dose reduction (risk of severe hypoglycemia). - Beta‑blockers masking hypoglycemia symptoms. - High‑dose corticosteroids increasing insulin resistance. - MAO‑inhibitors potentiating hypoglycemic effect. - Thiazide diuretics causing hypokalemia.

Use with caution: - Oral hypoglycemic agents (e.g., sulfonylureas) may enhance glucose‑lowering effect. - ACE inhibitors may modestly increase insulin sensitivity. - Lipid‑lowering agents (statins) have minimal interaction but monitor liver function. - Antidepressants (SSRIs) may affect appetite and weight. - Contrast media used in imaging may transiently affect glucose control.